FDA Approval: TRUXIMA (RITUXIMAB-ABBS) — Type 5 - New Formulation or New Manufacturer
Oncology
Government source· FDAverify ↗HCPCS Level II code
—
No national Medicare fee schedule we hold prices J9312 — the Physician Fee Schedule lists it with status indicator E (2026 file). CMS fee schedules ↗
Code definition
Code
J9312
Code system
HCPCS Level II
Full description
Injection, rituximab, 10 mg
CLV Intelligence is tracking 5 policy changes that cite HCPCS J9312 between 2026-06-05 and 2026-07-08, drawn from 3 LCD/NCD coverage updates, 1 FDA notice and 1 proposed LCD. The changes span Hematology and Oncology. 2 are flagged critical or high priority.
Counts reflect the source documents CLV has matched to HCPCS J9312 to date; each links to the government publication that is authoritative. Monitored daily from CMS, the Federal Register, and Medicare Administrative Contractor publications.
Recent policy changes matched to J9312
Matched to this code by CLV analysis of each policy. The linked source document is authoritative.
Oncology
Government source· FDAverify ↗+ 3 more alerts — subscribe to view
Search J9312 across all alerts
Full history of CMS and MAC policy changes matched to this code.
Audit documentation
The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get alerts when policy changes affect J9312
Free weekly digest — no subscription required.
Get the free 90-day policy snapshot for your specialty
Get a free 90-day sample snapshot — a PDF of every CMS and MAC policy change we tracked for your specialty and jurisdiction in the last quarter. Delivered instantly.
By downloading, you agree to receive related policy update emails. You can unsubscribe at any time. Privacy policy